H.Res.1285

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Introduced·5/14/26

The bill expresses the House of Representatives' sense that mifepristone, a medication for abortion, is safe and effective, and that access to it.

The bill emphasizes the importance of respecting over 25 years of evidence and hundreds of peer-reviewed studies that demonstrate mifepristone's safety and effectiveness. It calls for equitable, transparent, and science-based policies governing access to medication abortion care. The bill highlights the disproportionate impact of abortion restrictions on marginalized communities, including Black and Indigenous people, people of color, immigrants, those with lower incomes, people in rural areas, LGBTQ+ individuals, people with disabilities, and those experiencing intimate partner violence.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Energy And Commerce Committee
Next
Committee decision

Sponsors

Democratic CaucusRepublican Caucus

History

May 14

House

Submitted in House

May 14

House

Referred to the House Committee on Energy and Commerce.